In addition to considering subgroups of participants without a history of CVD or cancer at baseline, we conducted a sensitivity analysis that excluded the first two years of follow-up, to avoid the possibility that ANA levels could be impacted by late stage disease and imminent death. The gene discussed is BTG3; the disease is cancer.